Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, with limited survival outcomes due to tumor recurrence, mainly driven by GBM cell invasion and therapy resistance. Although temozolomide (TMZ) remains the standard‐of‐care chemotherapeutic, its long‐term ef...

Descripción completa

Detalles Bibliográficos

Autores principales:	Victoria A. Kriuchkovskaia, Ela K. Eames, Sydney A. McKee, Paul J. Hergenrother, Rebecca B. Riggins, Brendan A. C. Harley
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley-VCH 2026-06-01
Colección:	Advanced NanoBiomed Research
Materias:	chemotherapy resistance glioblastoma (GBM) hydrogel methylguanine methyltransferase (MGMT) temozolomide (TMZ)
Acceso en línea:	https://doi.org/10.1002/anbr.202500244
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!